FORM 8.1(a) & (b) - Mural Oncology plc

Ap9FORM 8.1(a) & (b) (Opening Position Disclosure)IRISH TAKEOVER PANELOPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE1.        KEY INFORMATION(a)     Full name of discloser: Mural Oncology plc (b)     Owner or controller of interests and shortpositions disclosed, if different from 1(a):The naming of nominee or vehicle companies isinsufficient. For a trust,...
Comunicato Precedente

next
Comunicato Successivo

next

Ap9

FORM 8.1(a) & (b)
(Opening Position Disclosure)

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE

1.      KEY INFORMATION

(a)   Full name of discloser: Mural Oncology plc
(b)   Owner or controller of interests and shortpositions disclosed, if different from 1(a):

The naming of nominee or vehicle companies isinsufficient. For a trust, the trustee(s), settlor andbeneficiaries must be named.
N/A
(c)   Name of offeror/offeree in relation to whoserelevant securities this form relates:

Use a separate form for each offeror/offeree
Mural Oncology plc
(d)   Is the discloser the offeror or the offeree? Offeree
(e)   Date position held:

The latest practicable date prior to the disclosure
29 April 2025
(f)   In addition to the company in 1(c) above, is thediscloser also making disclosures in respectof any other party to the offer?

If it is a cash offer or possible cash offer, state“N/A”
N/A


2.
      INTERESTS AND SHORT POSITIONS

If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap10

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1)

Class of relevant security: (Note 2)
  Interests Short positions
  Number % Number %
(1)   Relevant securities ownedand/or controlled: NIL - NIL -
(2)   Cash-settled derivatives: NIL - NIL -
(3)   Stock-settled derivatives(including options) andagreements to purchase/sell: NIL - NIL -
Total: NIL - NIL -


All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.      INTERESTS AND SHORT POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE

  Details of any interests and short positions (including directors'and other employee options) of any person acting in concert withthe party making the disclosure:
a) The directors of the Offeree detailed in the table below (together with their connected persons under Rule 3.3(b)(ii) of Part A of the Irish Takeover Rules) have the following interests in the Offeree
Director Class of Relevant Security Number of ordinary shares held at midnight on 29 April 2025 Percentage of total issued share capital (rounded) Total number of ordinary shares underlying outstanding stock options, restricted share units and other subscription rights
Caroline Loew Ordinary shares of US$0.01 each 43,622 0.25%   865,908
Scott Jackson Ordinary shares of US$0.01 each 23,483
Francis Cuss Ordinary shares of US$0.01 each 23,483
George Stanley Golumbeski Ordinary shares of US$0.01 each 15,334
Benjamin Hickey Ordinary shares of US$0.01 each 23,483
Sachiyo Minegishi Ordinary shares of US$0.01 each 15,335
TOTAL - 43,622 0.25%   967,026


Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

Ap11

4.      OTHER INFORMATION

(a)      Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreementor understanding, formal or informal, relating to relevant securitieswhich may be an inducement to deal or refrain from dealingentered into by the party to the offer making the disclosure or anyperson acting in concert with it:
 
Irrevocable commitments and letters of intent should not be included. Ifthere are no such agreements, arrangements or understandings, state“none”

None



(b)
      Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understandingbetween the person disclosing and any other person relatingto the voting rights of any relevant securities under any optionreferred to on this form or relating to the voting rights or futureacquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, thisshould be stated.

None



(c)
      Attachments

Is a Supplemental Form 8 attached? YES/NO
  No


Date of disclosure: 30 April 2025
Contact name: Maiken Keson-Brookes
Telephone number: +1 781 614 0239


Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.

Ap12

NOTES ON FORM 8.1(a) and (b)

1.         See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.

2.         See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.

3.      If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.


Ufficio Stampa

 Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti

Allegati
Slide ShowSlide Show
Non disponibili
;